GLP-1 receptor agonists × glycemic control

TrialDiabetes, obesity & metabolism2015

Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study.

J Miyagawa et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 492 people · 2015

Randomised comparison

Probably lowered glycemic control

−1.57percentage points−1.79 to −1.35

As reported

difference −1.57 %, 95% CI −1.79 to −1.35

One number in the abstract

the abstract, start to end

mean difference: dulaglutide vs placebo -1.57% (95% confidence interval -1.79

← favours treatmentfavours comparator →
could be chance
Glycemic control
−1.57−1.79 to −1.35
GLP-1 receptor agonistsGlycemic control

GLP-1 receptor agonists × glycemic controlhelps?replicated

unlikelylikely
0.910.91 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

54 papers cite it

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 26179187